stockportfolio.pro
Enovis Corporation (ENOV)
Healthcare · Medical Devices · NYSE
Enovis Corporation revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.19B | $1.94B | $2.19B | $3.33B | $1.12B | $1.43B | $1.56B | $1.71B | $2.11B | $2.25B |
| Gross profit | $992.38M | $671.58M | $729.38M | $1.40B | $603.64M | $777.67M | $869.38M | $990.78M | $1.18B | $1.35B |
| Net income | $128.11M | $151.09M | $140.20M | $-527.65M | $42.63M | $71.66M | $-13.29M | $-33.26M | $-825.49M | $-1.18B |
| Net margin | 4.0% | 7.8% | 6.4% | -15.9% | 3.8% | 5.0% | -0.9% | -1.9% | -39.2% | -52.7% |
Source: Enovis Corporation SEC filings (10-K). 17 years of history available in the interactive view.
What growth is priced into ENOV stock?
At today's market cap of $1.28B, Enovis Corporation is priced for free-cash-flow growth of about 23.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $19.92M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -36.1%/yr over the last five fiscal years and revenue 14.9%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 17 years of Enovis Corporation financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ENOV in your portfolio →
Enovis Corporation financial history by metric
About Enovis Corporation
Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.
Enovis Corporation — frequently asked questions
What is Enovis Corporation's revenue?
Enovis Corporation (ENOV) reported revenue of $2.25B for fiscal year 2025, up 6.7% from the prior year, according to its SEC filings.
Is Enovis Corporation profitable?
No — ENOV reported a net loss of $-1.18B in fiscal 2025.
What is ENOV's P/E ratio?
Enovis Corporation trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Enovis Corporation growing?
ENOV's revenue grew at roughly 14.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Enovis Corporation have?
As of fiscal year 2025, ENOV carried roughly $1.30B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Enovis Corporation's gross margin?
ENOV's gross margin was 59.8% in fiscal 2025 — gross profit of $1.35B on revenue of $2.25B.
What is Enovis Corporation's market cap?
Enovis Corporation (ENOV) has a market capitalization of about $1.28B, based on the latest data in our nightly-refreshed cache.
When does Enovis Corporation's fiscal year end?
ENOV's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ENOV stock?
At today's market cap of $1.28B, Enovis Corporation is priced for free-cash-flow growth of about 23.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $19.92M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -36.1%/yr over the last five fiscal years and revenue 14.9%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Enovis Corporation's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.